Tirzepatide for Type 2 Diabetes

Finding: Largest/most recent SR-MA (14 RCTs, 14,713 patients): dose-dependent HbA1c reduction vs placebo (SMD -1.45 at 5 mg [95% CI -1.68 to -1.21], -1.59 at 10 mg [-1.82 to -1.37], -1.56 at 15 mg [-1.85 to -1.27]) and body-weight reduction (SMD up to -1.80 at 15 mg [-2.12 to -1.49]), with high heterogeneity (I2 up to 93%) and no increased hypoglycaemia.

Finding: Umbrella review of 6 meta-analyses (8 unique RCTs, 7,245 participants): overall HbA1c -1.94% (95% CI -2.02 to -1.87) and body weight -8.4 kg (95% CI -9.6 to -7.2) vs placebo/control, both dose-dependent (HbA1c -1.79% at 5 mg to -2.09% at 15 mg).

Finding: SR-MA of 9 RCTs: dose-dependent HbA1c reduction vs placebo (-1.50% at 5 mg to -1.80% at 15 mg), vs GLP-1 RA (-0.61% to -0.95%) and vs basal insulin (-0.70% to -1.09%), with dose-dependent weight loss and no increase in hypoglycaemia but more GI adverse events.

Finding: SR-MA of 6 trials (6,579 subjects; 4,410 tirzepatide / 2,054 control): HbA1c WMD -1.07% (95% CI -1.44 to -0.56) and body weight WMD -7.99 kg (95% CI -11.36 to -4.62) vs control, without increased hypoglycaemia; more GI adverse events (mainly add-on) but no significant increase in pancreatitis or cholelithiasis.

Finding: Network meta-analysis: tirzepatide 15 mg superior to weekly insulin for HbA1c (MD -1.27, 95% CI -1.49 to -1.00) and body weight (MD -12.13 kg, 95% CI -13.98 to -10.27) with lower hypoglycaemia risk, but higher rates of adverse events and treatment discontinuation at higher doses; total sample size not reported in the abstract/open metadata.

Finding: First dedicated hard-endpoint CVOT (13,165 analyzed; 13,299 randomized): tirzepatide noninferior to the CV-protective comparator dulaglutide for 3-point MACE (12.2% vs 13.1%; HR 0.92, 95.3% CI 0.83-1.01; noninferiority P=0.003) but did NOT meet superiority (P=0.09) — i.e. CV SAFETY established, not CV benefit; the HR 0.84 all-cause-mortality figure is a non-confirmatory secondary endpoint absent from the primary-paper abstract.